atai Life Sciences Announces Pricing of Upsized Initial Public Offering

Articles | June 17, 2021

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. All common shares are being offered… Read More

atai Life Sciences Announces Launch of Initial Public Offering

Articles | June 11, 2021

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common shares. All common shares to be sold in the proposed offering will be sold by atai. The underwriters… Read More

Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia

Articles | April 6, 2021

Recognify Life Sciences, Inc., an atai Life Sciences platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive Impairment Associated with Schizophrenia (CIAS), today announced it has initiated a Phase 2a study for its lead compound RL-007, after receiving IND clearance from the Food and Drug… Read More

Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders

Articles | March 16, 2021

Perception Neuroscience, an atai Life Sciences company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd., announce a collaboration and licensing agreement for the development and commercialization of Perception’s lead molecule, PCN-101 (R-ketamine) in Japan as a potential treatment for mood disorders such as major depressive… Read More

atai Life Sciences Announces Strategic Partnership with IntelGenx

Articles | March 15, 2021

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) today announced that its wholly owned subsidiary, IntelGenx Corp., a leader in pharmaceutical films, has agreed to the terms of a strategic partnership with atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, including an equity investment… Read More

atai Life Sciences’ DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK

Articles | March 10, 2021

DemeRx IB, Inc., an atai Life Sciences platform company focused on developing ibogaine for the treatment of opioid use disorder, today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency to commence subject enrolment in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002). Read More

atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round

Articles | March 3, 2021

atai Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D financing round. The round was led by our existing investors Apeiron Investment Group, the family office of atai’s founder Christian Angermayer, Thiel Capital, and… Read More

atai Life Sciences’ Perception Neuroscience’s PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Study

Articles | February 19, 2021

Perception Neuroscience, an atai Life Sciences biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced positive data from its first Phase 1 clinical study demonstrating the safety and tolerability of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of ketamine that is being developed for therapeutic treatment of psychiatric… Read More

atai Life Sciences’ EmpathBio announces joint feasibility assessment of Bionomics’ BNC210 and EmpathBio’s MDMA derivative EMP-01 treatment regimen for PTSD

Articles | February 17, 2021

Bionomics Limited today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc, a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences. Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics’ BNC210 and EmpathBio’s… Read More

Schizophrenia

Mission | November 16, 2020

It is estimated that schizophrenia affects over 21 million people globally and approximately 2.4 million people in the United States. Approximately 300,000 new cases are diagnosed each year in the United States. People with schizophrenia are two to three times more likely to die early than the general population, with… Read More